While their competitor AbbVie seeks to undo jury verdicts worth nearly $290 million over testosterone replacement therapy drugs, drugmaker Auxilium has received a clean bill from a jury in its first court test over claims it and other similar drugmakers should be made to pay for alleged misleading marketing that led men to take the drugs, and suffered heart attacks as a result.
After two federal juries delivered $140 million verdicts against AbbVie, competing drugmaker Auxilium will be headed to trial over claims its testosterone replacement therapy drug Testim caused heart attacks in men who took the drug to treat “off-label” conditions, spurred by what plaintiffs alleged was misleading marketing from drugmakers.
For now, a Chicago federal judge has permitted a onetime student's suit to proceed against the University of Chicago, saying, while the student must furnish a more full explanation, he has squeaked out a plausible case a school official encouraged retaliation against him for complaining about sexual assault allegations.
Judges: Asbestos plaintiff not harmed by ruling barring testimony from doctor over exposure theories
A federal appeals court in Chicago has refused to upend a jury’s verdict against a retired pipefitter, who had claimed Owens-Illinois and ExxonMobil should be held liable for his lung cancer because possible exposure to asbestos on work sites decades ago, and not a 30-year, pack-and-a-half-a-day cigarette smoking habit, had caused the illness.
A Springfield federal judge has placed Dish Network on the hook for a fine of more than $280 million for alleged violations of federal telemarketing law, even though the violations were committed by third-party contractors. And other companies should take note of the judge's ruling, said a lawyer who specializes in defenses against similar legal actions.